Enter the last name, specialty or keyword for your search below.
Tireless in his advocacy, and on the dance floor, surgeon Dorry Segev is on a mission to make organs more widely available for those who desperately need them.
Nerve damage in neuropathy progresses sooner than previously thought, lending urgency to earlier detection and treatment.
Biomedical engineer Warren Grayson shares his step-by-step recipe, complete with ingredients and serving suggestions, for creating missing bone.
Pregnant women have been excluded from the clinical research agenda for too long, say bioethicists and medical specialists. Spurred on by the Zika crisis, they are pushing to close that knowledge gap.
Stroke too often gets missed, with tragic consequences, in emergency departments across the country. Here’s how high-tech “stroke goggles” could help.
A new center for Zika treatment, celebrating a Lasker, high-intensity treatment for high-use patients, defending against cyberattacks and more.
A laser focus for epilepsy, sweating it out, sickle cell and opioids, looking to the biofilm in colon cancer, and more.
Randall Packard tells where efforts to improve global health have fallen short. Plus: Essays on the history of the Children’s Medical and Surgical Center (in a nod to the Lane), and what to do when antidepressants fail.
The scientific community is getting serious about fixing the replication problem in research.
More than 300 people from Johns Hopkins marched in the annual Baltimore Pride Parade in July, a celebration of the LGBTQ community. Led by a “scrubs rainbow” and accompanied by a Lifeline ambulance and a Blue Jay shuttle, the Johns Hopkins crowd’s enthusiasm earned it the Best Walking Group award in the parade.
In 2017, The Johns Hopkins Hospital will join a growing number of leading academic medical centers in offering gender-affirming therapies for transgender patients, including sex reassignment surgery and hormonal treatment, as part of a range of support options available.
Watch a video featuring Johns Hopkins participants in the Pride Parade.
Two classes of compounds already in the pharmaceutical arsenal may work against mosquito-borne Zika virus infections, says a research team, including Johns Hopkins researchers, which screened 6,000 existing compounds currently in late-stage clinical trials or already approved for human use for other conditions.
The screening process identified several compounds, reported in Nature Medicine in August, that showed the ability to hinder or halt the progress of the Zika virus in lab-grown human neural cells.
“It takes years, if not decades, to develop a new drug,” says Hongjun Song, director of the stem cell biology program at Johns Hopkins. “In this sort of global health emergency, we don’t have that kind of time.”
Next up: studies of the drugs in animals to see if they can combat Zika in vivo.
Save the Date!
You can choose to support a specific cause at Johns Hopkins about which you are passionate, or you can make a contribution that will support our priorities in research, patient care and medical education.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
